Hinrich P Hansen

Summary

Publications

  1. ncbi Human CD30: structural implications from epitope mapping and modeling studies
    Liying Dong
    Institut fur Medizinische Immunologie, Universitatsklinikum Charite, Humboldt Universitat zu Berlin, Berlin, Germany
    J Mol Recognit 16:28-36. 2003
  2. ncbi CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme
    H P Hansen
    Departments of Biochemistry and Anatomy, University of Kiel, Kiel, Germany
    J Immunol 165:6703-9. 2000
  3. ncbi Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin
    Hinrich P Hansen
    Department of Biochemistry, University of Kiel, Kiel, Germany
    Int J Cancer 98:210-5. 2002
  4. doi ADAM17-overexpressing breast cancer cells selectively targeted by antibody-toxin conjugates
    Ahmad Trad
    Institute of Biochemistry, Christian Albrechts University of Kiel, Olshausenstr 40, 24098, Kiel, Germany
    Cancer Immunol Immunother 62:411-21. 2013
  5. ncbi Vitronectin- and fibronectin-containing immune complexes in primary systemic vasculitis
    Karen Maehnss
    University of Kiel, Germany
    J Autoimmun 18:239-50. 2002
  6. ncbi Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivo
    Baerbel Matthey
    Medizinische Klinik I der Universitat zu Koln, Cologne, Germany
    Int J Cancer 111:568-74. 2004
  7. ncbi The ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5
    Hinrich P Hansen
    Department of Internal Medicine I, University Hospital Cologne, LFI, Ebene 4, Room 703, Joseph Stelzmann Str 9, 50924 Cologne, Germany
    FASEB J 18:893-5. 2004
  8. pmc Selective killing of B-cell hybridomas targeting proteinase 3, Wegener's autoantigen
    Katrin S Reiners
    Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany
    Immunology 112:228-36. 2004
  9. ncbi Simvastatin-dependent apoptosis in Hodgkin's lymphoma cells and growth impairment of human Hodgkin's tumors in vivo
    Bastian Von Tresckow
    Laboratory of Immunotherapy, Clinic I of Internal Medicine, University Hospital Cologne, Cologne, Germany
    Haematologica 92:682-5. 2007
  10. ncbi ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro
    Dennis A Eichenauer
    Department of Internal Medicine I and Center for Molecular Medicine, University Hospital Cologne, Kerpener Strasse 62, 50924 Cologne, Germany
    Cancer Res 67:332-8. 2007

Collaborators

  • Stefan Rose-John
  • R Mentlein
  • G Murphy
  • Andreas Engert
  • Stephen J Davies
  • Peter Borchmann
  • Katrin S Reiners
  • Roland Schnell
  • Andreas Ludwig
  • Elke Pogge Von Strandmann
  • Bastian Von Tresckow
  • Hilmar Lemke
  • Ahmad Trad
  • Hans Lange
  • Dennis A Eichenauer
  • Samir Tawadros
  • Baerbel Matthey
  • Liying Dong
  • Regina Fölster-Holst
  • Karen Maehnss
  • Inken Lorenzen
  • Katja Klausz
  • Christine Desel
  • Joachim Grötzinger
  • Mohammad Shomali
  • André Mauermann
  • Matthias Peipp
  • Nina Hedemann
  • Kosuke Yamamoto
  • Paul Saftig
  • Vijaya Lakshmi Simhadri
  • Stephanie Sasse
  • Vance Matthews
  • Andreas Draube
  • Sabine Merkert
  • Michael Hallek
  • Ingvill Purr
  • Marcel Reiser
  • Venkateswara R Simhadri
  • Stefan Barth
  • Mehmet K Tur
  • Michael Huhn
  • Alexander Klimka
  • Karl Josef Kallen
  • Martin Hülsmeyer
  • Horst Dürkop
  • Barbara Uchanska-Ziegler
  • Andreas Ziegler
  • Jens Schneider-Mergener
  • Enno Christophers
  • Wolfgang L Gross
  • Michael Weichenthal
  • Jörg Kobarg
  • Elena Csernok
  • Jörg Wehde
  • Wilhelm H Schmitt
  • Tilo Henseler

Detail Information

Publications13

  1. ncbi Human CD30: structural implications from epitope mapping and modeling studies
    Liying Dong
    Institut fur Medizinische Immunologie, Universitatsklinikum Charite, Humboldt Universitat zu Berlin, Berlin, Germany
    J Mol Recognit 16:28-36. 2003
    ....
  2. ncbi CD30 shedding from Karpas 299 lymphoma cells is mediated by TNF-alpha-converting enzyme
    H P Hansen
    Departments of Biochemistry and Anatomy, University of Kiel, Kiel, Germany
    J Immunol 165:6703-9. 2000
    ..Hence, TACE does not only control the release of TNF-alpha, but also that of sCD30...
  3. ncbi Inhibition of metalloproteinases enhances the internalization of anti-CD30 antibody Ki-3 and the cytotoxic activity of Ki-3 immunotoxin
    Hinrich P Hansen
    Department of Biochemistry, University of Kiel, Kiel, Germany
    Int J Cancer 98:210-5. 2002
    ..dgA towards the CD30(+) Hodgkin-derived cell line L540. Hence, the metalloproteinase inhibitor BB-3644 may be a promising compound to improve the immunotherapy of CD30(+) malignancies...
  4. doi ADAM17-overexpressing breast cancer cells selectively targeted by antibody-toxin conjugates
    Ahmad Trad
    Institute of Biochemistry, Christian Albrechts University of Kiel, Olshausenstr 40, 24098, Kiel, Germany
    Cancer Immunol Immunother 62:411-21. 2013
    ..These data suggest that the use of anti-ADAM17 monoclonal antibodies as a carrier might be a promising new strategy for selective anti-cancer drug delivery...
  5. ncbi Vitronectin- and fibronectin-containing immune complexes in primary systemic vasculitis
    Karen Maehnss
    University of Kiel, Germany
    J Autoimmun 18:239-50. 2002
    ..However, their involvement in the pathogenesis of the disease is not clearly defined. Our data suggest that there are preformed IC present in sera of patients with CSS and WG that contain VN and FN and bind to endothelial cells...
  6. ncbi Metalloproteinase inhibition augments antitumor efficacy of the anti-CD30 immunotoxin Ki-3(scFv)-ETA' against human lymphomas in vivo
    Baerbel Matthey
    Medizinische Klinik I der Universitat zu Koln, Cologne, Germany
    Int J Cancer 111:568-74. 2004
    ..Thus, concomitant application of metalloproteinase inhibitors might become clinically relevant in antibody-based immunotherapy against targets known to be shed from tumor cells...
  7. ncbi The ectodomain shedding of CD30 is specifically regulated by peptide motifs in its cysteine-rich domains 2 and 5
    Hinrich P Hansen
    Department of Internal Medicine I, University Hospital Cologne, LFI, Ebene 4, Room 703, Joseph Stelzmann Str 9, 50924 Cologne, Germany
    FASEB J 18:893-5. 2004
    ..These data suggest that CD30 shedding is stimulated by an elevated local availability of CRD2 or 5, possibly by forming a docking station for the releasing enzyme through substrate aggregation...
  8. pmc Selective killing of B-cell hybridomas targeting proteinase 3, Wegener's autoantigen
    Katrin S Reiners
    Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany
    Immunology 112:228-36. 2004
    ..The data indicate that autoantigen-toxins are promising tools in the treatment or co-treatment of autoimmune diseases in which the antigen is known...
  9. ncbi Simvastatin-dependent apoptosis in Hodgkin's lymphoma cells and growth impairment of human Hodgkin's tumors in vivo
    Bastian Von Tresckow
    Laboratory of Immunotherapy, Clinic I of Internal Medicine, University Hospital Cologne, Cologne, Germany
    Haematologica 92:682-5. 2007
    ..Since the prenylation-inhibitors FTI-277 and GGTI-298 were also effective against HL-cells, we conclude that statins and specific prenylation-inhibitors should be evaluated in HL patients...
  10. ncbi ADAM10 inhibition of human CD30 shedding increases specificity of targeted immunotherapy in vitro
    Dennis A Eichenauer
    Department of Internal Medicine I and Center for Molecular Medicine, University Hospital Cologne, Kerpener Strasse 62, 50924 Cologne, Germany
    Cancer Res 67:332-8. 2007
    ....
  11. ncbi A novel bispecific protein (ULBP2-BB4) targeting the NKG2D receptor on natural killer (NK) cells and CD138 activates NK cells and has potent antitumor activity against human multiple myeloma in vitro and in vivo
    Elke Pogge Von Strandmann
    Laboratory of Immunotherapy, Department I for Internal Medicine, University Hospital of Cologne, Kerpener Str 62, D 50924 Koln, Germany
    Blood 107:1955-62. 2006
    ..The use of recombinant NK receptor ligands that target NK cells to tumor cells might offer new approaches for other malignancies provided a tumor antigen-specific antibody is available...
  12. ncbi Soluble CD30 plasma concentrations correlate with disease activity in patients with atopic dermatitis
    Regina Fölster-Holst
    Department of Dermatology, Christian Albrechts University of Kiel, Germany
    Acta Derm Venereol 82:245-8. 2002
    ..This study demonstrates a correlation between sCD30 concentration and the activity of the disease and therefore suggests sCD30 as a prognostic marker, being superior to predictions from measurements of IgE or eosinophil cationic protein...
  13. ncbi Depletion of cellular cholesterol and lipid rafts increases shedding of CD30
    Bastian Von Tresckow
    Department of Internal Medicine I, University Hospital Cologne, Cologne, Germany
    J Immunol 172:4324-31. 2004
    ..Our results suggest a possible role of cholesterol-dependent shedding of CD30 in the pathogenesis of immune diseases...